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Abstract.  Cellular interactions with fibronectin-treated 
substrata have a complex molecular basis involving 
multiple domains.  A  carboxy-terminal cell and heparin 
binding region of fibronectin (FN) is particularly in- 
teresting because it is a  strong promoter of neurite 
outgrowth (Rogers, S.  L., J.  B.  McCarthy,  S.  L. Palm, 
L. T.  Furcht,  and P. C.  Letourneau,  1985. J.  Neu- 
rosci.  5:369-378) and cell attachment (McCarthy, 
J.  B.,  S. T.  Hagen, and L.  T. Furcht.  1986. J.  Cell 
Biol.  102:179-188.).  To further understand the molec- 
ular mechanisms of neuronal  interactions with this re- 
gion of FN,  we screened two peptides from the 33-kD 
heparin binding fragment of the FN A  chain,  FN- 
C/H II (KNNQKSEPLIGRKKT) and CS1 (Humphries, 
M. J., A.  Komoriya, S. K.  Akiyama, K.  Olden,  and 
K.  M.  Yamada.  1987. J.  Biol.  Chem.  262:6886- 
6892),  for their ability to promote B104 neuroblas- 
toma cell-substratum adhesion and neurite outgrowth. 
Both FN-C/H U and CS1 promoted B104 cell attach- 
ment in a concentration-dependent and saturable man- 
ner,  with attachment to FN-C/H II exceeding attach- 
ment to CS1. In solution, both exogenous FN-C/H II 
or CS1 partially inhibited cell adhesion to the 33-kD 
fragment.  Similar results were obtained with anti-FN- 
C/H II antibodies.  In contrast,  soluble GRGDSP did 
not affect B104 cell adhesion to FN-C/H II. These 
results indicate that both FN-C/H II and CS1  represent 
distinct,  RGD-independent,  cell adhesion-promoting 
sites active within the 33-kD fragment,  and further 
define FN-C/H II as a novel neural recognition se- 
quence in FN. B104 adhesion to FN-C/H II and CS1 
differs in sensitivity to heparin,  yet each peptide in- 
hibited adhesion to the other peptide, suggesting cell 
adhesion is somehow related at the cellular level. 
Within the A  chain 33-kD fragment,  FN-C/H U and 
CS1 are contiguous, and might represent components 
of a larger domain with greater neurite-promoting  ac- 
tivity since only the 33-kD fragment,  and neither 
individual peptide, was effective at promoting B104 
neurite outgrowth.  These data further support the hy- 
pothesis that cell responses to FN are mediated by 
multiple sites involving both heparin-sensitive and 
-insensitive mechanisms. 
T 
hE  extracellular  matrix  (ECM) 1 is a  complex mix- 
ture of components that  plays an  important  role in 
regulating  cell shape and behavior, thus affecting em- 
bryonic development and cellular differentiation.  One ECM 
glycoprotein of  much interest is fibronectin (FN), which pro- 
motes cell adhesion and motility  (Couchman et al.,  1982; 
McCarthy et al., 1988), and affects morphogenesis and em- 
bryonic cell migrations  (Boucaut et al., 1984a,b; Dufour et 
al., 1988a; for review see Furcht, 1981; Hynes, 1985; Ruos- 
lahti,  1988;  Yamada,  1989).  FN may function  in nervous 
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system development  by promoting  the outgrowth  of axons 
from peripheral nervous system (PNS) neurons (Carbonetto 
et al., 1983; Rogers et al., 1983, 1989), and is present along 
pathways of neural crest cell migration  in a spatial and tem- 
poral expression that correlates with the localization  of neu- 
ral  crest  cells  (Duband  and  Thiery,  1982a,b;  Bronner- 
Fraser,  1986; Dufour et al.,  1988b;  for review  see Sanes, 
1989).  In  the  central  nervous  system  (CNS),  FN  im- 
munoreactivity has been noted as well, restricted to particu- 
lar  regions  and  stages  of development  that  correlate  to 
specific neuronal migrations  and neurite outgrowth (Stewart 
and Pearlman,  1987; Chun and Shatz,  1988). For example, 
FN promotes retinal neurite outgrowth  (Akers et al.,  1981; 
Hall et al., 1987). It is clear that FN may have diverse roles 
in developmental  interactions  with a variety  of cells. 
Cell adhesion to FN has a complex molecular basis involving 
multiple cell-atlachment domains. The arginyl-glycyl-aspartyl- 
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a sequence that promotes cell attachment (Pierschbacher and 
Ruoslahti, 1984a, b; McCarthy et al., 1986), and plays a role 
in neurite outgrowth (Rogers et al., 1987; Waite et al., 1987; 
Letourneau et al., 1988; Mugnai et al., 1988b).  Cells inter- 
act with the RGDS cell attachment sequence in FN through 
an o~5/31 integrin-dependent mechanism (Pytela et al., 1985; 
Horwitz et al., 1985; Ruoslahti and Pierschbacher, 1987; for 
review see Buck and Horwitz, 1987; Hynes, 1987).  RGDS 
is unable to account for all of the cell adhesion- and neurite- 
promoting activity of FN (Rogers et al., 1985, 1987; Izzard 
et al., 1986; McCarthy et al., 1986; Waite et al., 1987), indi- 
cating that molecules other than the RGD-specific integrins 
also mediate cell recognition of FN. 
The carboxy-terminal cell and heparin binding region of 
FN promotes RGD-independent cell attachment (McCarthy 
et aI.,  1986;  Izzard et al.,  1986;  Liao et al.,  1989) and is 
a strong promoter of neurite outgrowth (Rogers et al., 1985, 
1987; Waite et al., 1987). Rogers et al. (1985, 1987) demon- 
strated that neurons from the PNS and CNS attach to and 
extend neurites on substrata treated with a 33-kD proteolytic 
fragment of fibronectin from the carboxy-terminal heparin 
binding region of the A chain. High concentrations of solu- 
ble RGD-containing peptide do not inhibit neuronal adhe- 
sion nor decrease neurite length on surfaces coated with the 
33-kD heparin binding fragment (Rogers et al., 1987). CNS 
neurons actually prefer the heparin binding fragment as a 
substratum over the intact FN molecule, and are able to form 
stable neurites on the isolated heparin binding domain of FN 
even though they do not form stable neurites on surfaces 
coated with intact FN (Rogers et al., 1985). In contrast, PNS 
neurons form stable neurites on either substratum (Rogers 
et al., 1985), demonstrating an example of  different neuronal 
responses to specific FN domains. 
One way to further elucidate the molecular basis for cell 
adhesion to the carboxy-terminal heparin binding domain of 
FN has  been to generate synthetic peptides representing 
potential cell adhesion sequences within this region. Previ- 
ous studies have identified three such peptides from within 
the heparin binding region that have RGD-independent cell 
attachment activity. CS1 (DELPQLVTLPHPNLHGPEILD- 
VPST) is found within the alternately spliced IIIcs region of 
the A isoform of FN (Kornblihtt et al., 1985) and promotes 
cell-specific adhesion and spreading of melanoma cells (Hum- 
phries et al., 1987; McCarthy et al., 1990),  as well as PNS 
neurite outgrowth (Humphries et al., 1988). Recently, it has 
been demonstrated that ot4/~l integrin mediates hematopoi- 
etic cell adhesion to the CS1 sequence (Wayner et al., 1989; 
Guan and Hynes, 1990;  Mould et al., 1990).  Two heparin- 
binding peptides from within the 33-kD fragment that pro- 
mote melanoma cell adhesion have also been isolated: FN-C/H 
I  (YEKPGSPPREVVPRPRPGV)  and FN-C/H  II  (KNN- 
QKSEPLIGRKKT) (McCarthy et al., 1988). These peptides 
differ from CS1 in their ability to bind heparin (McCarthy 
et al., 1988), and FN-C/H II differs from FN-C/H I in that 
it is contiguous with CS1. 
In this study, we focused on the response of neural cells 
to defined sequences from the carboxy-terminai heparin bind- 
ing domain of  FN by contrasting FN-C/H II and CS1 for their 
ability to promote neuroblastoma adhesion. The response of 
neural cells to FN-C/H II has not previously been described. 
Our data support the hypothesis that FN-C/H II represents 
a  specific RGD-independent neuronal cell attachment se- 
quence within the carboxy-terminal cell and heparin binding 
domain of FN. Neuroblastoma adhesion to the C-terminal 
heparin binding region of the FN A chain involves multiple 
sites,  since CS1 is also active within this domain. Further, 
the A  chain-derived 33-kD  fragment, but neither peptide 
alone, promotes neurite outgrowth, suggesting that FN-C/H 
II and CS1, which are contiguous within this fragment, are 
contained in a larger domain. Cell adhesion to FN-C/H II 
differs from cell adhesion to CS1 in sensitivity to heparin, 
yet each peptide inhibits cell adhesion to the other peptide, 
implying cell adhesion to these two distinct peptides is some- 
how coordinated at the cellular level. 
Materials and Methods 
Cell Lines 
The neuroblastoma cell line, BI04,  isolated by in vivo mutagenesis and 
generously donated by Dr. D.  Schubert (Salk Institute), expresses several 
neuronal characteristics, including electrical excitability, neurotransmitter 
synthesis, and neurite-like process formation (Schubert et al.,  1974). Cells 
were maintained free of mycoplasma contamination, in DME (Gibco Lab- 
oratories, Grand Island, NY), buffered with bicarbonate, and supplemented 
with 100 ng/ml penicillin-streptomycin, 0.25 ttg/ml fungizone, 2 mM L-glu- 
tamine (Gibco Laboratories),  7.5% calf serum, and 2.5%  FBS (Hyclone 
Laboratories,  Logan,  UT). 
Protein, Fragment, and Peptide Preparation 
Human plasma FN was purified as a byproduct of Factor VIII production 
by  sequential  ion-exchange  and  gelatin  affinity  chromatography  as  de- 
scribed (McCarthy  et al.,  1986).  A  2-min trypsin digest followed by a 
cathepsin D digest produced the 75-kD and 33-kD fragments as described 
previously (McCarthy et al.,  1986; see Fig.  1 for fragment location). 
Peptides were synthesized at the University of Minnesota Microchemical 
Facility by Dr. Robert Wohlheuter using a peptide synthesizer (System 990; 
Beckman Instruments, Fullerton, CA). The procedures used are based on 
the  Merrifield solid-phase system as  described  previously  (Stewart and 
Young,  1984).  Lyophilized  crude peptides  were purified by preparative 
reverse-phase HPLC on a C-18 column, using an elution gradient of 0-60% 
acetonitrile with 0.1% trifluoroacetic acid in water. The purity and composi- 
tion of the peptides were routinely verified by HPLC analysis of hydroly- 
sates prepared by treating the peptides under nitrogen in 6 N HC1 overnight 
at ll0°C,  and the sequence was verified on the sequenator (McCarthy et 
al., 1988; Chelberg et al., 1989). The FN peptides specifically used for this 
study  are:  FN-C/H  II (formerly  termed "Peptide  IF;  McCarthy  et al., 
1988),  representing  residues  1,946-1,960  (KNNQKSEPLIGRKKT(Y)), 
CS1  with a  primary  sequence of DELPQLVTLPHPNLHGPEILDVPST 
(Humphries et al.,  1987) and GRDGSP, representing residues 1,492-1,497 
(based on sequence information from Kornblihtt et al.,  1985). FN-C/H II 
was synthesized with a tyrosine residue on the cerboxy terminal end to allow 
for iodination (see below). The sequences shown use the single letter amino 
acid code (K =  lysine, R  =  arginine, H  =  histidine, E  =  glutamic acid, 
D  =  aspartic acid, Q  =  glutamine, N  =  asparagine, P  =  proline, G  = 
glycine, S =  serine, T  =  threonine, V  =  valine, I  =  isoleucine, L  =  leu- 
cine, Y  =  tyrosine). 
Coupling of  Peptides to Ovalbumin (OA  ) 
Peptides FN-C/H II and CS1  were coupled to ovalbumin as suggested by 
Humphries et al. (1987), based on a procedure by Bauminger and Wilchek 
(1980). Briefly, equal amounts (by weight) of peptide and ovalbumin were 
solubilized and mixed with a  10-fold excess (by weight) of 1-ethyl-3(3-di- 
methylaminopropyl)-carbodiimide hydrochloride (Sigma Chemical Co., St. 
Louis, MO) dissolved in water. After mixing overnight at 4"C, the sample 
was extensively dialyzed in PBS to remove excess cerbodiimide and tmcou- 
pied peptide (10,000-D exclusion; Spectrum Medical Industries, Los An- 
geles, CA). 
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Antibodies 
Polyclonal antibodies were generated against FN peptides coupled to key- 
hole limpet hemocyanin (KLH; Sigma Chemical Co.) using carbodiimide 
as a coupling reagent, as described above, however for the dialysis proce- 
dure, dialysis tubing with a  1,000-D exclusion (Spectrapore 6; Spectrum 
Medical Industries) was used to remove only the excess carbodiimide and 
not the uncoupled peptide. This mixture was then concentrated in Aqnacide 
II (Calbiochem-Behring Corp., La Jolla, CA) to a final concentration of 10 
mg/rnl, and aliquots were stored at -70°C. The coupling of the peptide to 
KLH was verified by the use of radioiodinated FN-C/H II in a parallel reac- 
tion mixture. 
The coupled mixture was then used tO immunize New Zealand White 
rabbits. Immunization was performed by mixing an equal volume of pep- 
tide/KLH conjugate with CFA, and injecting this mixture into multiple sites 
on the shaved backs of the rabbits (,~1 mg of conjugate/rabbit). Subsequent 
biweekly boosts in incomplete Freund's adjuvant were given in one shot in- 
tramuscularly. Sera was collected 14 d after the fourth immunization, and 
tested by ELISA (see below) for reactivity against proteins and uncoupled 
synthetic peptides. 
ELISA plates (either Immulon I or C; Dynatech Laboratories, Chantilly, 
VA) were prepared by adsorbing 1 #tg of the synthetic peptides, FN, 33-kD 
fragment,  control proteins,  and  control peptides into  each  well,  using 
Voller's carbonate buffer to dilute the ligands (Smith and Furcht, 1982). The 
plates were then blocked by incubating the wells for 2 h at room temperature 
with PBS containing 2 mg/ml of ovalbumin (PBS/OA). Various concentra- 
tions of antisera or purified IgG were diluted in PBS containing 0.05% 
Tween 20 and 0.36 M  NaC1 (PBS/Tween) and incubated in the wells for 
1 h at room temperature on a rotating platform. The plates were washed 
three times with PBS/Twcen and incubated an additional hour with a 1:500 
dilution of peroxidase conjugated goat anti-rabbit immunoglobulin (Cappel 
Laboratories,  Malvern,  PA).  The  plates  were washed extensively with 
PBS/Tween and developed with the subsequent addition of 0.4 mg/mlg of 
orthophenylene diarnine containing 0.012%  H202  in 0.1 M  sodium phos- 
phate and 24 mM citric acid. The reaction was terminated by the addition 
of 2.5 M H2SO4 and the intensity at 490 um was determined using an auto- 
matic microplate reader (EL311;  Bio-Tek Instruments, Burlington, VT). 
Cell Adhesion and Spreading Assays 
Substrata were prepared using two different procedures. FN, proteolytic 
fragments of FN, and synthetic peptides were diluted to the appropriate con- 
centrations in Voller's carbonate buffer. If peptides had not been conjugated 
to OA, they were adsorbed onto 96-well tissue culture plastic (Costar Corp., 
Cambridge, MA) overnight in a dry oven at 29°C. If peptides were con- 
jugated to OA, they were adsorbed to Immulon 1 plates in a humidified oven 
at 37°C overnight. Nonspecific sites were blocked the next day with 5 mg/rnl 
of BSA (fatty acid-free; Miles Scientifc, Naperville, IL) in Dulbecco's PBS 
(DPBS), pH 7.4, for 2-3 h. Control wells were adsorbed with either a 5-mg/ 
ml solution of BSA or nothing, then blocked with BSA in DPBS; the results 
were the same using either method. Before the addition of cells, the sub- 
strata were rinsed three times with DPBS. Nearoblastoma ceils were de- 
tached from tissue culture plastic using cold PBS without calcium or mag- 
nesium at pH 7.4 for 15 min followed by mild mechanical disruption. After 
centrifugation, cells were placed in FI2H-BHSA medium, composed of F12 
medium (Gibco Laboratories) buffered with 20 mM Hepes, pH 7.4 (Sigma 
Chemical Co.) containing 5 mg/ml BSA. Cells were resuspended to 50,000 
cells/ml and 100 t~l was added to each well. Cells were allowed to attach 
for 1 h at 37°C, in 5% CO2.  Nonadherent cells were removed by rinsing 
with 370C DPBS three times. Adherent cells were fixed with 2% glutaralde- 
hyde for 20-40 min and counted visually using phase-contrast microscopy 
with a 10x objective on a Nikon inverted scope. Cells observed in one di- 
ameter across each well, 3.5 field of views, were counted. The percent cells 
attached equals the number of cells counted divided by the number of cells 
expected for 3.5 fields if 100% of the cells seeded in a well attached in an 
even distribution. A second method of quantitating adherent cells was also 
esed that assays the amount of hexosaminidase  enzyme present (Landegren, 
1984;  see below). All experiments were performed at least twice. 
To quantitate cell spreading, glutaraldehyde fixed cells were stained for 
48 h with 0.2% toluidine blue in 0.1 N acetic acid. The surface area oc- 
cupied by cells was measured using a Nikon microscope with a 20x objec- 
tive interfaced with an Optomax video analysis system and Apple lie com- 
puter (Chelberg et al., 1989). At least 20 fields, containing a total of at least 
60 ceils, were measured in each case. 
Hexosaminidase Assay for Quantitating 
Adherent Cells 
To quantitate adherent cells more quickly, the following assay based on the 
procedure of Landegren (1984)  was used. After the third rinse in DPBS, 
60 t~l of hexosaminidase substrate (3.75 mM p-Nitrophenol-N-aceytl-~/-v- 
glucosaminide, 50 mM citrate, 0.25%  Triton X-100)  was added to each 
well, and incubated for 21-24 h at 37°C. The assay was stopped and the 
color developed by the addition of 90 t~l of 50 mM glycine buffer, 5 mM 
EDTA, pH 10.4. Absorbances were measured using a plate reader (EL311; 
Bio-Tek Instruments) at 405 urn. For each assay, a standard curve was con- 
structed using known numbers of cells to determine the number of cells ad- 
hered to the substrata. Additionally, duplicate plates that had been fixed and 
counted using phase microscopy verified the accuracy and sensitivity of this 
method. 
Determination of  Peptide Binding to Plastic Wells 
Peptides FN-C/H II and CS1 were radiolabeled with 125Iodine (New En- 
gland  Nuclear,  Boston,  MA)  using  an  aqueous  chloramine T  reaction 
(Hunter and Green~x>d, 1962).  Briefly, 0.5 mCi of 125I was added to a 1.0 
ml Reacti vial (Pierce Chemical Co., Rockford, IL) containing 100/~g of 
peptide, 0.2 M  sodium phosphate buffer, and 50 ~g/ml chloramine T  in 
phosphate buffer (Sigma Chemical Co.). After allowing the reaction to pro- 
ceed for 2 rain, 200 t~g/ml NaHSO3  was added to stop the reaction. Pep- 
tide was separated from unreacted t2sI by separation on a  Sep-Pak C18 
column (Millipore Corp.,  Milford,  MA).  After extensive washing with 
0.2 M sodium phosphate buffer,  125I-peptide was eluted with a 50% aceto- 
nitrile, 0.1% trifluoroacetic acid solution. Eluate was aliquoted and lyophi- 
lized. Radiolabeled peptides were conjugated to OA as described above. 
The 33- and 66-kD proteolytic fragments of FN were labeled with 0.5 mCi 
of [3H]formaldehyde (New England Nuclear) by reductive methylation as 
previously described (Jentoft and Dearborn, 1979; Herbst et al., 1988). Ra- 
diolabeled peptides (both OA-conjugated and unconjugated) and proteolytic 
fragments were diluted in Voller's carbonate buffer and substrata prepared 
as described above for adhesion assays. The next day, the wells were treated 
with 5 mg/ml BSA in DPBS for 2-3 h, then rinsed three times in DPBS 
to duplicate adhesion assay conditions. Peptide remaining bound was solu- 
bitized with 0.5 N NaOH and 1% SDS, and bound radioactivity was quanti- 
tated in a liquid scintillation counter (LS 3081;  Beckman Instruments) or 
a GammaTrac gamma counter (TM Analytic, Elkgrove Village, IN). The 
amount of peptide bound was calculated based on the amount of radiolabel 
recovered and the specific activity of the peptide. 
Peptide and Antibody Inhibition Assays 
Substrata and cells were prepared as described above for the adhesion as- 
says. Whenever an assay involved a soluble inhibitor, the substratum coating 
concentration used was one near the concentration that promoted half- 
maximal adhesion for that protein, fragment, or peptide. This concentration 
was different for peptides that had been conjugated to OA compared with 
those that had not. For peptide inhibition assays, cells at 50,000 cells/ml 
were incubated at 37°C for 25-30 min in F12H-BSA containing various 
concentrations of soluble peptides. After this incubation, the mixture of 
cells and peptide was plated directly into wells and ceils were allowed to 
attach for 40 rain, or until they were observed to begin attaching and spread- 
ing on FN-coated surfaces. For antibody inhibition assays, various concen- 
trations of  purified anti-FN-C/H II IgG or normal rabbit IgG were incubated 
in the wells for 30 min. Cells were then added to the wells and allowed to 
attach for 40-50 min. For both types of assays, nonadherent cells were re- 
moved by rinsing, and adherent cells were fixed and counted. 
Heparin (and Sulfated Polyanion) Inhibition 
Substrata and cells were prepared as described above for the adhesion as- 
says. Substrata were incubated at 370C for 25 rain with F12H-BSA contain- 
ing various concentrations of soluble heparin (Sigma Chemical Co.). After 
three rinses in PBS, 5000 ceils in 0.1 rnl were added to each well and in- 
cuhated at 370C until cells were observed to begin attaching and spreading 
on substrata. Nonadherent cells were removed by rinsing, and adherent cells 
were quantitated by visually counting or assaying hexosaminidase. The 
same procedure was used for other sulfated polyanlons. Dextran sulfate and 
bovine kidney heparan sulfate were obtained from Sigma Chemical Co. 
Chondroitin-4-sulfate from rat chondrosarcoma was a generous gift of Dr. 
Theodore Oegema (University of Minnesota). The charge characteristics of 
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Figure 1. Location of the 33- and 66-kD heparin binding fragments 
and the synthetic peptide sequences within the intact FN molecule. 
Also depicted is the location of the l]Ics region found only on the 
A isoform of human plasma FN. The amino and carboxy ends of 
the 33-kD fragment are based on previous sequence data (McCar- 
thy et al., 1988). Selected biological domains, indicated by roman 
numerals  at the  top,  are based  on the  nomenclature  of Furcht 
(1981). L weak heparin binding; II, collagen binding; II1, free sulf- 
hydryl;  ~  RGD-mediated  cell  adhesion;  V,  carboxy-terminal 
strong heparin binding and cell adhesion; V1, free sulfhydryl. Loca- 
tion of tryptic  (T) and cathepsin  D  (C) sites on fibronectin are 
shown. 
each polyanion  are not specifically  known, but dextran sulfate is expected 
to be the most highly polyanionic, followed by heparin. Chondroitin-4- 
sulfate and heparan sulfate  are less highly charged, with chondroitin sulfate 
likely more anionic than heparan sulfate. 
Results 
Neuroblastoma Cells Adhere to Multiple Sites 
Vc~thin the Carboxy-Terminal Heparin Binding 
Region of FN A  Chains 
The rat neuroblastoma cell line used for this study, B104, is 
a useful model to study neural responses to FN domains be- 
cause one can isolate large quantities of cells for future char- 
acterization of molecules involved in adhesion.  B104 cells 
are  electrically excitable,  synthesize  neurotransmitter  en- 
zymes, and are able to extend long,  thin neurite-like pro- 
cesses (Schubert et al.,  1974,  1986;  Tobey et al.,  1985). 
B104 cells are able to attach and spread on intact FN (not 
shown). 
Digestion of FN with trypsin and cathepsin-D yields a 33- 
kD heparin binding fragment from the A chain, containing 
a portion of the differentially spliced lllcs region, and a 66-kD 
heparin binding fragment from the B chain, lacking the IIIcs 
region (Fig.  1; McCarthy et al.,  1986). We determined the 
response of B104 cells to these fragments using three pa- 
rameters: adhesion, spreading, and neurite outgrowth. B104 
ceils adhered in a concentration dependent manner on sub- 
strata  coated  with  either  heparin  binding  fragment,  but 
showed a greater adhesive response to the A chain (33-kD) 
compared to the B chain (66-kD) derived fragment. After a 
1-h incubation, more than twice as many B104 cells adhered 
to substrata coated with the 33-kD fragment than to sub- 
strata coated with equivalent or greater amounts of the 66- 
kD fragment (Fig. 2 A). The 33-kD fragment was also more 
effective at promoting B104 cell spreading than the 66-kD 
fragment. As seen with adhesion, cells cultured on 33-kD- 
treated substrata encompassed almost twice the surface area 
(in square microns) as cells cultured on 66-kD-treated sub- 
strata (Fig. 2 B). In fact, spreading on the 33-kD fragment 
slightly exceeded spreading on intact FN (not shown).  At 
higher coating concentrations (100 #g/ml), B104 cells showed 
some spreading on the 66-kD-coated substratum. 
Using radiolabeled FN fragments, we determined whether 
differences in B104 cell response to the 33- and 66-kD frag- 
ments were due to differences in binding of each fragment 
to the plastic plates.  Differences in binding and molecular 
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Figure 2. Adhesion and spreading  of B]04 neural cells on substrata 
treated with the A or B chain-derived fibronectin heparin binding 
fragments. B104 cells were allowed to attach to tissue culture wells 
coated with the 33-kD fragment (open squares) or the 66-kD frag- 
ment (solid diamonds) (as in Materials and Methods) and counted 
for cell attachment (A) or measured using computer-assisted image 
analysis for spreading (B). Each value represents the mean of  tripli- 
cate wells. Error bars represent the standard deviation (SD). Cell 
attachment is expressed as the percent of the total number of cells 
added/well that remained attached. 
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to Plastic Wells 
Coating  Input  Bound 
concentration  FN fragment  FN fragment 
/~  g /ml  pmol/we  U 
100  246  7.0 
30  69  7.2 
10  22  4.2 
3  4.5  1.6 
100  143  12.0 
30  38  4.9 
10  15  3.4 
3  3.4  1.5 
33-kD fragment 
66-kD fragment 
The 33- and 66-kD COOH-terminal heparin binding fragrmmts of FN were 
radiolabeled with 3H by reductive methylation (Materials and Methods). La- 
belod fragments were then serially diluted and adsorbed to plastic wells exactly 
as was done for the adhesion assay in Fig. 2. Using the input disintegrations 
per minute, the specific activity, and the molecular weight of each fragment, 
the amount of input FN fragment for each well (0.1  ml/well) was calculated. 
Based on disintegrations per minute recovered, the amount of FN fragment 
bound to each well was then calculated. 
weights between the two fragments do not account for the 
greater adhesion and spreading activity of the 33-kD frag- 
ment, since similar molar amounts of  both the 33- and 66-kD 
fragments were bound at each coating concentration tested 
(Table I). 
In addition to effectively promoting B104  cell adhesion 
and spreading, the 33-kD heparin binding fragment promot- 
ed neurite outgrowth. Neurite-like process  formation was 
scored after cells were cultured for 24 h, to allow B104 ceils 
sufficient time to extend neurites, on substrata coated with 
the 33- or 66-kD fragments. B104 cells extended long, thin 
processes on a substratum coated with 20/~g/ml of the 33-kD 
fragment (Fig. 3 A). B104 cells spread, but extended only 
short processes on a substratum coated with 100/~g/ml of 
the 66-kD fragment (Fig. 3 B). From these observations, it 
appears the 33-kD fragment may contain a neurite-promoting 
activity absent in the 66-kD fragment. 
Two previously described cell adhesion promoting syn- 
thetic peptides from within the 33-kD fragment were exam- 
ined for their ability to promote B104 cell adhesion. Peptide 
CS1, which is present only in plasma FN A-chains (Hum- 
phries et al., 1987) has been shown to promote cell adhesion 
by an o~4B1 integrin (Wayner et al.,  1989;  Mould et al., 
1990).  A  second  synthetic  peptide,  termed  FN-C/H  II 
(fibronectin cell and heparin binding peptide II), has been 
previously shown to promote melanoma cell adhesion and 
spreading (McCarthy et al., 1988) and is present within all 
isoforms  of  FN.  FN-C/H  II  has  been  shown  to  bind 
[3H]heparin,  whereas CS1  is inactive in this regard (Mc- 
Carthy et al.,  1988, 1990).  These two peptides represent 
contiguous sequences on plasma FN A-chains (Fig.  1). 
The synthetic peptides were coupled to a carrier protein, 
OA, since this had been shown to improve the ability of CS1 
to promote melanoma cell adhesion and spreading (Hum- 
phries et al., 1987). We quantitated the OA-coupling efficien- 
cies and binding of peptide-OA to the wells using radiola- 
beled peptides (Table II).  CS1 exhibited a two-fold higher 
coupling efficiency to OA than FN-C/H II. The amount of 
peptide-OA bound to the wells was similar whether FN-C/H 
II  or CS1  was coupled to the OA  (m40-50%  binding at 
1 /~g/mi OA).  However,  due to the different coupling stoi- 
chiometries, more CS1 bound than did FN-C/H II at each 
coating concentration. 
B104 cells adhered to substrata treated with either FN- 
C/H II-OA or CS1-OA in a  concentration dependent and 
saturable manner (Fig. 4). OA conjugated to itself (OA-OA) 
did not promote cell adhesion. As a substratum, FN-C/H II- 
OA was more active at promoting B104 adhesion than CS1- 
OA. FN-C/H II-OA maximally  promoted adhesion of m70% 
of the cells, while CS1-OA maximally promoted ,~50% cell 
adhesion. To reach half of this maximum adhesion required 
treatment of the substrata with a greater concentration of 
CSI-OA than FN-C/H II-OA. When the concentration of OA 
was used as a basis for determining a coating concentration 
of 1 ~,g/ml, 4.5 pmoles of FN-C/H II promotes adhesion of 
50% of the cells, while 6.1 pmol of CS1 promotes adhesion 
of only 20% of the cells. Similar results were obtained for 
unconjugated FN-C/H II and CS1 (not shown). 
B104 cells also spread on substrata coated with either pep- 
tide conjugate (not shown). Within 1 h, both peptides pro- 
moted spreading of *80-90% of adherent cells. In contrast 
to what was previously observed on the intact 33-kD frag- 
ment (Fig.  3 A),  cells cultured overnight on either of the 
these two peptide-OA conjugates did not exhibit long, neu- 
ronal processes (Fig. 3, C and D). Instead, the cell morphol- 
ogy on the two synthetic peptides resembled that observed 
on the 66-kD heparin binding fragment, with short, stubby 
processes being formed by these cells (compare Fig. 3 B with 
Cand D). 
Peptides FN-C/H H and CSI Both Represent 
RGD-independent Cell Adhesion Promoting Sites 
within the 33-kD Heparin Binding Fragment 
Cell adhesion to CS1 has previously been shown to be RGD- 
independent  (Humphries  et  al.,  1988;  McCarthy  et  al., 
1990). Attachment  of  B104 cells to FN-C/H II was also RGD 
independent (Fig. 5). B104 cells were incubated in various 
concentrations of soluble GRGDSP before allowing them to 
attach to surfaces treated with FN, the 75-kD FN fragment 
that contains an RGD sequence, or FN-C/H II. Soluble pep- 
tide was present throughout the assay. Soluble GRGDSP in- 
hibited B104 adhesion to substrata coated with the 75-kD 
fragment or FN in a concentration-dependent manner, with 
600  #g/ml of GRGDSP  causing 57  and  19%  inhibition, 
respectively (Fig. 5). This concentration of soluble GRGDSP 
had no effect on the adhesion of B104 cells to a FN-C/H II- 
coated substratum (Fig. 5), demonstrating that FN-C/H II is 
an RGD-independent site of cell adhesion. 
Additional experiments were performed to establish that 
FN-C/H II represents an active site within the 33-kD frag- 
ment. As one approach, cell attachment assays were performed 
in the presence of increasing concentrations of purified IgG 
generated against FN-C/H II. An ELISA confirmed that this 
IgG reacted with FN-C/H II and intact FN (Table I~, The 
antibody did not react with laminin, FN-C/H I (a different 
FN peptide that binds heparin and promotes cell adhesion), 
or OA. 
In functional assays, anti-FN-C/H II IgG inhibited the at- 
tachment of B104 cells to a FN-C/H 1I substratum (Fig. 6). 
Haugen et al. Multiple  Sites in the FN Heparin Binding Region  2737 Figure 3. B104 process formation in response to the FN heparin binding region. B104 neural cells were cultured  for 24 h on substrata 
treated with: (A) 20 #g/ml of the 33-kD (A chain-derived) fragment, (B) 100 #g/ml of the 66-kD (B chain-derived) fragment, (C) 1 #g/ml 
of  FN-C/H II-OA, (D) or 2 #g/ml of  CS1-OA. Except for the 33-kD fragment, these concentrations all induce cell spreading to the maximum 
cell surface area observed for each given peptide in 1-h assays. Arrows in A point to long, neurite-like processes.  Bar, 30 #m. 
At the highest concentration of IgG tested (500 gg/ml), inhi- 
bition of cell adhesion to a  surface coated with FN-C/H II 
was virtually complete (,x,80% inhibition). This concentra- 
tion of anti-FN-C/H II IgG also significantly decreased at- 
tachment of B104 cells to surfaces coated with the 33-kD 
heparin binding FN fragment or intact FN by ~35 % (Fig. 
6). As expected, the anti-FN-C/H II IgG had no effect on at- 
tachment of B104 cells to the 75-kD FN fragment. Normal 
rabbit IgG (500/~g/ml)  caused no significant inhibition of 
cell attachment (<8 % for any of the substrata tested). Simi- 
lar experiments were conducted  with anti-CS1  antibodies. 
However, these antibodies were of extremely low affinity in 
The Journal of Cell Biology, Volume 111, 1990  2738 Table II. Amount of  Peptide-OA  Bound to lmmulon-1 Wells 
Coating  Input  Bound 
(OA)  peptide/well  peptide/well 
#g/ml  pmol 
FN-C/H II  30  162  13 
10  68  9.1 
3  16  6.3 
t  9.1  4.5 
CS 1  30  362  35 
10  123  19 
3  36  11 
1  16  6.1 
FN-C/H  II and  CS1,  with  radiolabeled  125-I, were  conjugated  to OA  as 
described in Materials and Methods.  Coupling efficiencies of around  11%  for 
FN-C/H II and 39% for CSl were obtained. FN-C/H II coupled to OA with 
a stoichiometry of 2.9 tool of FN-C/H II to 1 mol of OA, while CS1 coupled 
with a stoichiometry of 6.3 mol of CS1 to 1 mol of OA. OA--conjugated pep- 
tides were then serially diluted and adsorbed to wells based on the known con- 
centration of OA (micrograms/milliliter),  as is done for adhesion assays. Using 
the input counts per minute and the coupling efficiency, the amount of input 
peptide for each well (0.1 ml/well) was calculated. Based on counts per minute 
recovered,  the amount of peptide bound to each well was then calculated. 
ELISA assays, and did not inhibit B104 adhesion to CS1 (not 
shown). 
As a second approach, the ability of exogenous FN-C/H 
II to inhibit cell adhesion on various FN-derived substrata 
was tested (Fig.  7).  B104 cells were preincubated with in- 
creasing concentrations of soluble FN-C/H II, then the mix- 
ture  of cells  and  soluble  peptide  was  added  to  substrata 
coated with various ligands.  Soluble FN-C/H U  inhibited 
cell  adhesion  in  a  concentration-dependent  and  saturable 
manner to surfaces coated with  FN-C/H U  or the 33-kD 
heparin binding  fragment (Fig.  7).  Maximal inhibition  of 
cell adhesion of FN-C/H II was  almost complete (84%), 
80 
60 
20 
0 
0.01  0.1  1  10  100 
Peptide  coating  concentration  (gg/ml) 
Figure 4. Adhesion of  Bl04 neural cells to FN-C/H ]I-OA and CS1- 
OA. B104 cells were allowed to attach to tissue culture wells treated 
with increasing concentrations of OA-conjugated FN-C/H II (open 
squares) and CS1 (solid diamonds). OA conjugated to itself (OA- 
OA) did not promote adhesion (solid squares). Cell adhesion was 
quantitated  by assaying the  amount  of hexosaminidase  enzyme 
(Materials and Methods), and is expressed as the percent of the to- 
tal cells added/well that remained attached.  Each value represents 
the mean of triplicate wells  +  the SD. 
6o 
40 
0  200  400  600 
Soluble  GRGDSP  (p.g/ml) 
Figure 5.  Effect of soluble GRGDSP on adhesion to FN-derived 
substrata.  B104 cells were incubated with increasing concentra- 
tions of soluble GRGDSP peptide before allowing the cells to attach 
to surfaces treated with 250 #g/ml of FN-C/H II (open squares), 
20/~g/ml of the 75-kD fragment (solid  squares), or 10/~g/ml of FN 
(open diamonds). Cell adhesion was quantitated by visual counting 
and is relative to the 100% control cell adhesion observed for each 
substratum in the absence of inhibitors. Values represent the mean 
of triplicate wells  +  the SD. 
whereas inhibition of cell adhesion on the 33-kD fragment 
was partial (39%).  Soluble FN-C/H II had no effect on cell 
attachment to a  surface coated with intact FN,  consistent 
with the hypothesis that multiple cell attachment sites medi- 
ate adhesion to the FN molecule. The specificity of inhibi- 
tion was demonstrated by the inability of soluble FN-C/H II 
to inhibit cell attachment to the 75-kD  (RGD-containing) 
FN fragment (Fig.  7). 
Similarly, soluble peptide CS1 also specifically inhibited 
B104  cell adhesion  to various  FN-derived cell  adhesion- 
promoting ligands (Fig.  8).  As has been shown previously 
for melanoma cells (McCarthy et al.,  1990),  soluble CS1 
virtually eliminated cell adhesion to CSl-coated substrata 
(Fig.  8).  Cell adhesion to substrata coated with the 33-kD 
fragment or FN was also partially inhibited ('~50% maxi- 
mum inhibition). As expected, soluble CS1 had no effect on 
adhesion  to the  75-kD  (RGD-containing)  fragment or an 
RGD-containing peptide (Fig.  8). 
Since either FN-C/H II or CS1 only partially inhibited cell 
adhesion to the 33-kD fragment, both peptides were added 
together in solution to determine if they would have an addi- 
tive effect on inhibiting cell adhesion to this fragment. A syn- 
ergistic effect was not seen since the addition of both peptides 
at concentrations as high as 500 #g/ml had no greater effect 
on B104 cell adhesion to the 33-kD fragment than either pep- 
tide alone (not shown).  These results suggest that CS1 and 
FN-C/H II may be promoting B104 cell adhesion by a related 
mechanism, and that additional adhesion-promoting deter- 
minants exist within the 33-kD fragment. 
FN-C/H II and CS1 Cross-Inhibit Cell Adhesion 
to Each Other 
To further study the relationship between CS1 and FN-C/H 
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Adsorbed antigen 
Anti-FN-C/H II 
antibodies  FN-C/H II  FN  LMN  FN-C/H I  OA 
pg/ml 
1  O. 144  0.000  0.000  000  0.028 
4  0.382  0.265  0.020  0.007  0.011 
20  0.644  O. 179  0.000  0.066  O.OOl 
100  0.746  0.600  0.000  0.093  0.017 
Plates were coated with 1/~g/well  of FN-C/H II or FN-C/H 1, and 3/~g/well  of FN, laminin  (LMN), or OA. Purified  IgG from rabbits immunized  with FN-C/H 
II coupled  to KLH was then added to the wells at the indicated  concentrations.  The ELISA  was performed  as described  in Materials  and Methods. and absorbance 
readings at 490 tun were taken. The values shown are an average of duplicate  wells with background readings  using normal rabbit IgG subtracted. Where the 
background reading exceeded  the absorbance  using anti-FN-C/H  II IgG, zero has been used. 
II, the ability of each peptide in solution to inhibit B104 cell 
adhesion to the other peptide was determined. As expected, 
preincubation  of B104  cells  with  soluble  FN-C/H  II-OA 
significantly inhibited cell adhesion to FN-C/H II-OA (Fig. 
9 A). Of interest, the addition of soluble FN-C/H II-OA in- 
hibited cell adhesion to CS1-OA by 58%  (Fig. 9  A).  Con- 
versely,  the  addition  of  soluble  CS1-OA  significantly in- 
hibited cell adhesion to both CS1-OA and  FN-C/H II-OA 
(Fig. 9 B). OA-OA had no effect on cell adhesion to either 
FN-C/H II-OA or CS1-OA (not shown),  indicating that the 
cross inhibition observed for the two peptides is not due to 
nonspecific effects of cross-linked OA. FN-C/H II-OA and 
CS1-OA did not inhibit adhesion to each other by directly 
binding to each other, since radiolabeled FN-C/H II-OA did 
not bind to a  substratum treated with CS1-OA, and radiola- 
beled CSl-OA did not bind to a substratum treated with FN- 
C/H II-OA (not shown). These results suggest that B104 cell 
adhesion to CS1 and FN-C/H II may somehow be related at 
the cellular level. 
Heparin Inhibits Cell Adhesion to FN-C/H II, 
But Not CS1 
Although FN-C/H II and CS1 are able to cross-inhibit B104 
cell adhesion to each other, these peptides differ in that FN- 
C/H II binds [3H]heparin, whereas CS1  does not.  Because 
of this difference, we compared the effect of exogenous hepa- 
rin on cell adhesion to substrata treated with CS1 or FN-C/H 
II.  Cell adhesion to FN-C/H II-OA is virtually eliminated 
when wells are pretreated with 100 ng/ml of soluble heparin, 
while cell adhesion to CS1-OA is unaffected (Fig. 10). These 
results suggest a distinction between the mechanism of cell 
adhesion to FN-C/H II and CS1. These results also indicate 
that  the ability of neural  cells to  attach to FN-CIH II is 
directly related to the heparin binding activity of FN-C/H II, 
consistent with a  role for a  cell-surface glycosaminoglycan 
or proteoglycan mediating cell adhesion to FN-C/H II. 
We next evaluated the specificity of heparin-mediated inhi- 
bition of cell adhesion on FN-C/H II-OA coated substrata by 
comparing the relative ability of other glycosaminoglycans 
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Figure 6. Inhibition of  Bl04 cell attachment by anti-FN-C/H H anti- 
bodies. Before the addition of cells,  substrata treated with 250 
/zg/ml of FN-C/H II (open squares), 20/zg/ml of the 33-kD frag- 
ment (solid diamonds), 10 gg/ml of FN (open diamonds), or 20 
tzg/ml of the 75-kD fragment (solid squares) were incubated with 
increasing concentrations of purified anti-FN-C/H H IgG. Adhe- 
sion was quantitated by visual counting. Values are relative to the 
adhesion observed in the absence of inhibitors (as in Fig. 5) and 
represent the mean of three wells +  the SD. 
Soluble  FN-C/H  II  (pg/ml) 
Figure 7. Inhibition of B104 cell attachment by soluble FN-C/H II. 
B104 neural cells were incubated with increasing concentrations of 
soluble FN-C/H II before allowing the cells to attach to surfaces 
treated with 250 ~g/rnl of FN-C/H II (open squares), 10 gg/ml of 
33-kD fragment (solid diamonds), 20 gg/ml of the 75-kD fragment 
(solid squares), or 10 t~g/ml of FN (open diamonds). Adhesion was 
quantitated by visual counting. Values are relative to the adhesion 
observed in the absence of inhibitors (as in Fig. 5) and represent 
the mean of three wells +  the SD. 
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Figure 8. Inhibition of B104 attachment by soluble CS1. B104 neu-  ~ 
ral cells were incubated with increasing concentrations  of soluble 
CS1 before allowing the cells to attach to surfaces treated with 1  o 
.m 
/zg/ml CS1-OA (open squares), 5 #g/m1 of the 33-kD heparin bind- 
ing fragment (solid diamonds), 20 gg/ml of the 75-kD fragment  " 
(solid squares),  1 /~g/ml of GRGDSP-OA (open triangles) or 10 
gg/ml of FN (open diamonds). Adherent cells were quantitated by  = 
means of the hexosaminidase enzyme assay (Materials and Meth- 
ods). Values are relative to the adhesion observed in the absence 
¢1 
of inhibitors  (as in Fig. 5) and represent the mean of three wells  > 
+  the SD.  _~ 
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to inhibit cell adhesion on this peptide (Fig.  11 A). Dextran 
sulfate was also included in these  studies as a  control for 
nonspecific charge effects of heparin.  While  both heparin 
and dextran sulfate were effective at competing for cell adhe- 
sion to FN-C/H II-OA, dextran sulfate was at least an order 
of magnitude less effective in this regard, suggesting that the 
heparin induced inhibition of B104 neural cell adhesion was 
not just due to nonspecific charge effects. Heparan sulfate 
glycosaminoglycans were  also  effective at  inhibiting  cell 
adhesion  to  FN-C/H  II-OA in  a  concentration-dependent 
manner; however, the amount required to produce a 50% in- 
hibition  was  two  orders  of  magnitude  greater  than  the 
amount of heparin which produced a similar degree of inhi- 
bition. Chondroitin 4-sulfate was not effective at competing 
for Cell  adhesion  to  FN-C/H  II-OA at any  concentration 
tested.  The ability of these sulfated glycoconjugates to in- 
hibit cell spreading on FN-C/H II-OA followed essentially 
an identical pattern (Fig.  11 B). These results are virtually 
identical to those observed using these sulfated glycocon- 
jugates to inhibit the binding of [3H]heparin to FN-C/H II 
(not shown). 
The  ability  of heparin  to  influence  cell  adhesion  and 
spreading  on  the  33-kD  fragment,  which  contains  both 
heparin-sensitive (FN-C/H II) and heparin-insensitive (CS1) 
sequences,  was also evaluated.  The addition of 1 gg/ml of 
heparin to substrata treated with the 33-kD fragment had a 
minimal effect on cell adhesion (~20% inhibition), but dra- 
maticaUy decreased B104 spreading. Process formation and 
the size to which  B104 cells could spread was noticeably 
affected (Fig.  12, compare A with B), suggesting both hepa- 
rin-sensitive  and  -insensitive  interactions  with  the  33-kD 
fragment are  necessary  for neuroblastoma  spreading  and 
neurite outgrowth. 
Discussion 
The carboxy-terminal heparin binding domain of plasma FN 
A-chains is a potent RGD-independent promoter of CNS and 
PNS neurite outgrowth (Rogers et al.,  1987;  Waite et al., 
1987). Furthermore, many other cell types have been shown 
to adhere to this fragment (Izzard et al., 1986; McCarthy et 
al.,  1986,  1990;  Liao et al.,  1989;  Wayner et al.,  1989; 
Visser et al.,  1989; Mould et al.,  1990), indicating a more 
general  biological role for this domain  in promoting cell 
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Figure 9.  Inhibition of B104 attachment  to synthetic peptides by 
soluble FN-C/H II and  soluble CS1. B104 neural  cells were in- 
cubated with increasing concentrations  of FN-C/H II-OA (.4) or 
CS1-OA (B) before allowing the cells to attach to surfaces treated 
with 1 /~g/ml FN-C/H II-OA (open squares) or 2 #g/ml CS1-OA 
(solid diamonds). Adherent cells were quantitated by means of the 
hexosaminidase enzyme assay (Materials and Methods). Values are 
relative to the adhesion observed in the absence of inhibitors  (as 
in Fig. 5) and represent the mean of three wells  +  the SD. 
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Figure 10.  Effect of soluble heparin on B104 cell adhesion. Wells 
adsorbed with. 2/Lg/ml CS1-OA or 1 #g/ml FN-C/H II-OA were 
preincubated with nothing (solid bars) or soluble heparin at 30 
ng/ml (hatched bars) or 100 ng/ml (dotted bars) of soluble heparin. 
Unbound soluble heparin was washed out, then B104 cells were 
added. Adherent ceils were quantitated by means of  the hexosamin- 
idase enzyme assay (Materials and Methods). Values are relative 
to the adhesion observed in the absence of inhibitors, and represent 
the average of three wells. 
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adhesion. The current studies were designed to further eluci- 
date the molecular basis of neuronal cell adhesion on this do- 
main of plasma FN A-chains. These results demonstrate that 
two structurally distinct peptides derived from this fragment 
can independently support neuroblastoma cell adhesion and 
spreading,  further supporting the hypothesis (McCarthy et 
al., 1988, 1990) that cell adhesion to this domain has a com- 
plex molecular basis  involving both heparin-sensitive and 
-insensitive mechanisms. 
Several lines of evidence indicate that both FN-C/H II and 
CS1 represent independent active sites within the 33-kD A 
chain-derived fragment. Both peptides are able to effectively 
compete for cell adhesion to this  fragment,  although the 
effect is only partial in either case. Specific anti-FN-C/H II 
IgG also partially inhibits cell adhesion to this fragment, fur- 
ther supporting the contention that FN-C/H H is exposed and 
active when in the context of the larger fragment. While the 
neurite-promoting activity of CS1 has previously been de- 
scribed (Humphries et al., 1988), these results indicate FN- 
C/H H also represents a site effective  at promoting neural cell 
adhesion. 
Although both FN-C/H II and CS1 promote RGD-inde- 
pendent neuronal cell adhesion,  each peptide has distinct 
structural and functional properties.  CS1  is relatively hy- 
drophobic, has a net negative charge, and fails to bind hep- 
arin. In contrast, FN-C/H II is hydrophilic, has a net posi- 
tive charge, and specifially binds [3H]beparin in solid phase 
binding assays (McCarthy et al., 1988). As expected, exoge- 
nous heparin was extremely effective at inhibiting neuronal 
cell adhesion to FN-C/H II, but was ineffective at inhibiting 
neuroblastoma cell adhesion to peptide CS1. Despite these 
differences, each of the two peptides could effectively cross- 
inhibit cell adhesion to the other peptide in our assays, sug- 
gesting that recognition of these two sequences within FN A 
chains is somehow linked at the cellular level. The ability of 
these peptides to cross-inhibit cell adhesion to each other 
was not due to nonspecific effects created by the opposite 
charges of these two peptides,  since the peptides did not 
directly bind each other. Considering the location of FN- 
C/H II immediately adjacent to CS1, one possibility is that 
FN-C/H II and CS1 bind two sites on the same molecule or 
two distinct molecules that are closely associated on the cell 
surface, although we have no evidence yet that indicates the 
exact relationship between these two sequences. 
This result is in sharp contrast to previous results examin- 
ing the ability of peptide CS1 to compete for melanoma cell 
adhesion to FN-C/H I, which represents an additional cat- 
ionic  heparin  binding/cell  adhesion  promoting  sequence 
within the 33-kD fragment (McCarthy et al,  1990). Those 
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Figure  11.  Effect  of sulfated  polyanJons  on  Bl04  adhesion  and 
spreading. BI04 neural ceils were cultured on a substratum treated 
with 1/~g/ml of FN-C/H H-OA that had been preincubated with in- 
creasing concentrations of soluble heparin (open squares), dextran 
sulfate (open  diamonds),  heparan  sulfate (solid diamonds),  or 
chondroitin-4-sulfate (solid squares).  Cell  adhesion  (A)  is  ex- 
pressed as the fraction of 100% adhesion to a FN-C/H II-OA sub- 
stratum when no inhibitor was present. Spreading (B) is expressed 
as the percent of attached cells that had spread to any extent and 
were no longer round. Values represent the average of triplicate 
wells +  SD. 
The Journal  of Cell Biology,  Volume 111, 1990  2742 Figure 12. Effect of soluble heparin on B104 cell spreading. B104 neural cells were cultured for 1 h on a substratum coated with 5 #g/ml 
of  the 33-kD heparin binding fragment which was (,4) untreated or (B) had been preincubated with 1 t~g/ml  of  soluble heparin. Bar, 30 ~tm. 
studies demonstrated that peptide CS1  was not effective at 
competing for cell adhesion to FN-C/H I coated substrata, 
and further argue that the ability of peptide CS1  to inhibit 
cell adhesion to FN-C/H II is not due to nonspecific charge 
effects. Unlike FN-C/H II, FN-C/H I is not contiguous with 
CS1, providing further evidence that the ability of CS1 and 
FN-C/H II to cross inhibit adhesion to each other may relate 
to their adjacent location. 
Several recent studies examining the molecular basis of 
cell adhesion to FN have suggested that multiple domains on 
the intact molecule mediate cell adhesion and modulate cell 
phenotype (Rogers et  al.,  1985,  1987;  Humphries et al., 
1987,  1988;  McCarthy et al.,  1986,  1990;  Dufour et al., 
1988b; Mugnai et al., 1988a; Obara et al., 1988; Wayner et 
al.,  1989; I~wandowska et al.,  1990). Our results support 
the view that multiple sites mediate cell responses to FN. 
CS1 and FN-C/H II are two such sites, and additional sites 
within the FN heparin binding fragment likely exist. While 
either FN-C/H II or CS1 alone is partially effective  at inhibit- 
ing cell adhesion to the 33-kD fragment, the simultaneous 
addition of both synthetic peptides in solution is not additive 
at inhibiting neuronal cell adhesion to the larger proteolytic 
fragment. This result suggests that interference of either site 
is sufficient to block cell adhesion to this domain, and that 
additional site(s) not blocked by soluble FN-C/H II and CS1 
promote neuronal cell adhesion to the 33-kD fragment. Our 
preliminary results demonstrate that FN-C/H I, which can 
promote melanoma cell adhesion (McCarthy et al.,  1988, 
1990) is also effective at promoting neuronal cell adhesion 
and may represent at least one additional site. 
The data presented here axe consistent with the hypothesis 
that both FN-C/H II and CS1 contribute to a larger domain 
within the 33-kD fragment that has high apparent affinity for 
cell surfaces. Both FN-C/H II and CS1 are present as a con- 
tiguous sequence on the 33-kD fragment. In contrast, the 
Mcs  region  containing  the  CS1  sequence  is  not  present 
within FN B chains (Kornblihtt et al., 1985), with the result 
that the 66-kD fragment contains FN-C/H II but lacks CS1. 
The 33-kD fragment is much more active at promoting neu- 
roblastoma adhesion, spreading, and neurite outgrowth than 
the 66-kD fragment, confirming previous results (McCarthy 
et ai.,  1986; Wayner et al.,  1989), and suggesting that the 
presence of peptide CS1 is essential for the neurite-like pro- 
cess formation observed on the 33-kD fragment. However, 
it is likely a heparin-sensitive interaction, such as binding to 
FN-C/H II, is also necessary for neuroblastoma cell spread- 
ing and neurite growth on the 33-kD fragment since soluble 
heparin inhibited B104 cell spreading on the 33-kD frag- 
ment.  Neither FN-C/H II or CS1  alone promoted neurite 
outgrowth, implying that both sequences must be within this 
larger domain to promote the formation of neurite-like pro- 
cesses by B104 ceils. These results are in contrast to previous 
studies that demonstrate that CSl  can support neurite out- 
growth of PNS neurons (Humphries et al.,  1988). This dif- 
ference could relate to the fact that the neuroblastoma cells 
used in the current studies are CNS cell lines and could differ 
from primary PNS neurons in the number and/or affinity of 
cell surface receptors for peptide CS1. Our results thus imply 
that CS1 acts in concert with heparin binding sites within FN 
A  chains to contribute to a  larger cell adhesion-promot- 
ing domain with higher affinity than that expressed on PN 
B-chains. 
It  will  be  extremely important  to  isolate  and  identify 
receptor(s) involved in neuronal cell adhesion to this domain 
of FN A-chains in order to understand the molecular basis 
for cell adhesion to the 33-kD fragment. An overwhelming 
literature exists which implicates cell surface proteoglycans 
in mediating cell adhesion to FN as well as other ECM pro- 
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Perris and Johansson,  1987; Saundcrs and Bcrnfield,  1988; 
Mugnai ct al.,  1988b; Culp,  1989;  for review see Hook et 
al.,  1984;  Gallagher et al.,  1986;  Margolis and Margolis, 
1989). In this study, we show that neural cell adhesion and 
spreading in response to FN-C/H II is extremely sensitive to 
exogenous heparin, indicating that cell adhesion to FN-C/H 
II may involve a heparin-like molecule on the cell surface. 
Additionally,  it has recently been demonstrated (Wayner et 
al.,  1989; Guan and Hynes,  1990; Mould et al.,  1990) that 
o~4fll integrin plays an important role in mediating the adhe- 
sion of several cell types to pcptidc CS1. One possible expla- 
nation for the high adhesive activity of the 33-kD fragment 
is that the contiguous sites within this fragment act in a coor- 
dinated manner to drive the lateral association of cell surface 
proteoglycans with other cell surface receptors (e.g.,  a4/~l 
integrins).  A  complete understanding,  at both the cellular 
and molecular level, of the mechanism of action of this frag- 
ment will help explain the mechanism by which ECM pro- 
teins such as FN modulate cell adhesion and phenotype. 
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